Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR1001 in mild to moderate Alzheimer's disease
NCT03625622Phase 2Completed
- Sponsor
- AriBio
- Start
- Apr 2019
- Primary completion
- Dec 2020
- Modality
- Covalent Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of mirodenafil in Alzheimer's disease (AD), sponsored by AriBio. Started Apr 2019; status: completed.
02
Drugs
mirodenafil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03625622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03625622.